Among nuclear receptors, FXR has a tumor-suppressive action that can prevent the beginning of CRC by modulating FXR-regulated transcriptional and epigenetic processes in intestinal cancer stem cells (105, 107, 108). This evidence concerns the gene NR1H4 and intestinal cancer.